United States was Cytek Biosciences’s largest region in fiscal 2025, bringing in $95.25M of $201.49M (47%).
| Geography | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| United States | $94.59M | $102.09M | $92.61M | $95.25M | |
| Emea | $43.96M | $53.18M | $62.34M | $55.88M | |
| Apac | $22.52M | $31.60M | $35.77M | $41.08M | |
| Other | $2.96M | $6.15M | $9.73M | $9.28M | |
| Total | $164.04M | $193.02M | $200.45M | $201.49M |
Cytek Biosciences brought in $201.49M from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 0.5% from $200.45M in fiscal 2024. United States was the largest at $95.25M (47.3%), ahead of Emea at $55.88M (27.7%) and Apac at $41.08M (20.4%). The remaining region, Other, brought in $9.28M.
Compared with fiscal 2024, Apac grew fastest, up 14.8% to $41.08M, while Emea fell the most, down 10.4% to $55.88M. From fiscal 2022 to 2025, combined revenue from these regions grew from $164.04M to $201.49M, a compound annual growth rate of 7.1%. United States' share of the total fell from 57.7% to 47.3%.
Biotechnology, Pharmaceutical, Distributor & Contract Research Organizations was Cytek Biosciences’s largest revenue line in fiscal 2025, bringing in $116.73M of $201.49M (58%).
| Customer | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Biotechnology, Pharmaceutical, Distributor & Contract Research Organizations | $90.33M | $110.87M | $119.54M | $116.73M | |
| Academia & Government | $73.71M | $82.15M | $80.91M | $84.76M | |
| Total | $164.04M | $193.02M | $200.45M | $201.49M |
Cytek Biosciences brought in $201.49M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 0.5% from $200.45M in fiscal 2024. Biotechnology, Pharmaceutical, Distributor & Contract Research Organizations was the largest at $116.73M (57.9%), ahead of Academia & Government at $84.76M (42.1%).
Compared with fiscal 2024, Academia & Government grew 4.8% to $84.76M, while Biotechnology, Pharmaceutical, Distributor & Contract Research Organizations fell 2.4% to $116.73M. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $164.04M to $201.49M, a compound annual growth rate of 7.1%. Biotechnology, Pharmaceutical, Distributor & Contract Research Organizations' share of the total rose from 55.1% to 57.9%.
Direct Sales Channel was Cytek Biosciences’s largest revenue line in fiscal 2025, bringing in $146.67M of $201.49M (73%).
| Contract with Customer, Sales Channel | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Direct Sales Channel | $129.10M | $147.17M | $149.87M | $146.67M | |
| Distributor Channel | $34.94M | $45.85M | $50.58M | $54.83M | |
| Total | $164.04M | $193.02M | $200.45M | $201.49M |
Cytek Biosciences brought in $201.49M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That was up 0.5% from $200.45M in fiscal 2024. Direct Sales Channel was the largest at $146.67M (72.8%), ahead of Distributor Channel at $54.83M (27.2%).
Compared with fiscal 2024, Distributor Channel grew 8.4% to $54.83M, while Direct Sales Channel fell 2.1% to $146.67M. From fiscal 2022 to 2025, combined revenue from these revenue lines grew from $164.04M to $201.49M, a compound annual growth rate of 7.1%. Direct Sales Channel's share of the total fell from 78.7% to 72.8%.
Cytek Biosciences (CTKB) reports its revenue by geography, by customer and by contract with customer, sales channel. In fiscal 2025, United States was its largest region, bringing in $95.25M (47.3% of the total), followed by Emea at $55.88M (27.7%).
United States was Cytek Biosciences' largest region in fiscal 2025, bringing in $95.25M, or 47.3% of the $201.49M total across its four regions.
Biotechnology, Pharmaceutical, Distributor & Contract Research Organizations was Cytek Biosciences' largest revenue line in fiscal 2025, bringing in $116.73M, or 57.9% of the $201.49M total across its two revenue lines.
Among Cytek Biosciences' regions that make up at least 2% of revenue, Apac grew fastest in fiscal 2025, up 14.8% from $35.77M to $41.08M.
Every figure comes from Cytek Biosciences' annual financial filings, as reported. Each line keeps the name Cytek Biosciences gives it, and years follow its fiscal calendar.
Cytek Biosciences' revenue by geography goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.